Completed PHASE4 INTERVENTIONAL 2-arm NCT02376803

The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The INRange RCT

Sponsor: University of Alberta

Conditions Atrial Fibrillation DVT Deep Venous Thrombosis Thromboembolism Thrombus Due to Heart Valve Prosthesis

Interventions Warfarin

Updated 7 times since 2017 Last updated: May 1, 2018 Started: Feb 28, 2015 Primary completion: Sep 30, 2016 Completion: Apr 27, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02376803, this PHASE4 trial focuses on Atrial Fibrillation and DVT and remains completed. Sponsored by University of Alberta, it has been updated 7 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Nov 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE4

▶ Show 2 earlier versions

Feb 2017 — Nov 2017 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Alberta
Vancouver Coastal Health Research Institute

Data source: University of Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada
• Vancouver, Canada